International Session 04 - (INTERACTIVE) Hypofractionation in the Global Context: Pathways to the Adoption of Evidence-Based Practice

8:00 AM - 9:00 AM
Location: Room W175

Session Type: Education
1.00 AMA PRA Category 1 Credits™
1.00 CAMPEP Credits
1.00 MDCB Credits

Hypofractionated radiotherapy, defined as the delivery of radiation in fractions >2 Gy/day, has been shown in multiple randomized controlled trials to be equivalent to conventionally fractionated treatment and to shorten the duration of treatment. Its routine use has the potential to reduce the cost of care, thereby facilitating the delivery of value-based care in high-income countries and access to radiotherapy in resource-constrained settings. Recent evidence from several new randomized controlled trials has expanded the indications for hypofractionated treatment, but its adoption internationally remains widely variable.

Presenters will review the most recent evidence on the indications for hypofractionation in breast and prostate cancer and will discuss specific technical and clinical indications for hypofractionation for these disease sites. They will also describe the results of an international survey on the adoption of hypofractionation for breast cancer, prostate cancer, cervical cancer, and bone metastases, and on barriers and facilitators to its adoption. They will consider the economic impact of hypofractionation in different regions, resource settings, and health care systems and describe international efforts now underway or in planning to advance the implementation of hypofractionated radiotherapy.

Learning Objectives:


Yolande Lievens, MD, PhD

Ghent University Hospital

Ghent University Hospital: Chair Radiation Oncology Department: Employee

College of Radiotherapy and Oncology Belgium: Deputy Chair;
ESTRO: Past-President

Yolande Lievens, MD, PhD, is the current chair of the radiation oncology department of the Ghent University Hospital in Ghent, Belgium, and associate professor at the Ghent University. She graduated from the Catholic University in Leuven, where she acquired her degrees in Medicine, Radiation Oncology and Hospital and Health Care Management, and completed her PhD in cost accounting and economic evaluation of
Her clinical focus lies on radiation therapy for thoracic malignancies, with an additional interest for the role of radiotherapy in hematology and breast cancer. Apart from the clinics, she has always been closely involved in the organizational aspects of radiotherapy, in the position of radiotherapy within multidisciplinary oncology and in the financial and health economic aspects of cancer care. Finally, she is interested in quality issues in radiation oncology, not only in terms of quality assurance but also regarding the impact of radiation treatments on quality of life.
She is past-president of ESTRO and deputy-chair of the Belgian College for Physicians in Radiation Oncology.
She is (co-)steering the Health Economics in Radiation Oncology (ESTRO-HERO), the Global Impact of Radiotherapy in Oncology (ESTRO-GIRO) and the E2-RADIATE (EORTC-ESTRO Infrastructure for Radiotherapy in Europe) projects.
She is convinced that an optimal combination of clinical, translational and health services research is key to the future of radiation oncology and to advance the outcome of cancer patients, by sustaining innovation in and access to radiotherapy in a multidisciplinary oncology environment.


Send Email for Yolande Lievens


International Session 04 - (INTERACTIVE) Hypofractionation in the Global Context: Pathways to the Adoption of Evidence-Based Practice

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for International Session 04 - (INTERACTIVE) Hypofractionation in the Global Context: Pathways to the Adoption of Evidence-Based Practice